AngioDynamics (NASDAQ:ANGO) Price Target Raised to $19.00

AngioDynamics (NASDAQ:ANGO) had its price objective lifted by HC Wainwright from $16.00 to $19.00 in a research report report published on Wednesday morning, Marketbeat reports. HC Wainwright currently has a buy rating on the medical instruments supplier’s stock. HC Wainwright also issued estimates for AngioDynamics’ Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at $0.01 EPS and FY2027 earnings at ($0.27) EPS.

ANGO has been the subject of a number of other reports. Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Canaccord Genuity Group boosted their price target on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

AngioDynamics Price Performance

Shares of AngioDynamics stock opened at $13.51 on Wednesday. The firm’s fifty day simple moving average is $12.24 and its 200-day simple moving average is $11.35. AngioDynamics has a 12 month low of $8.36 and a 12 month high of $15.19. The stock has a market capitalization of $558.37 million, a price-to-earnings ratio of -15.53 and a beta of 0.34.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The firm had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Analysts anticipate that AngioDynamics will post -0.27 earnings per share for the current year.

Institutional Trading of AngioDynamics

Hedge funds have recently made changes to their positions in the company. Kotler Kevin purchased a new stake in shares of AngioDynamics in the fourth quarter valued at approximately $21,997,000. Weber Capital Management LLC ADV purchased a new position in AngioDynamics in the fourth quarter worth $17,978,000. UBS Group AG raised its position in AngioDynamics by 83.6% in the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after acquiring an additional 501,881 shares in the last quarter. Millennium Management LLC lifted its holdings in AngioDynamics by 28.1% in the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after acquiring an additional 393,682 shares during the period. Finally, Nuveen LLC lifted its holdings in AngioDynamics by 40.5% in the fourth quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock valued at $16,629,000 after acquiring an additional 373,110 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on AngioDynamics and maintained a $19 price target, signaling confidence in the company’s longer-term upside despite ongoing losses. MarketBeat ANGO
• Positive Sentiment: An earlier report said AngioDynamics set a new 52-week high following an analyst upgrade, which likely reinforced bullish sentiment around the name. AngioDynamics Sets New 52-Week High Following Analyst Upgrade
• Neutral Sentiment: HC Wainwright cut several fiscal 2027 EPS estimates for AngioDynamics, including Q1, Q2, Q4, and full-year forecasts, reflecting a more cautious near-term earnings outlook. MarketBeat ANGO
• Neutral Sentiment: Despite the lower estimates, HC Wainwright still projects AngioDynamics will narrow losses over time, with FY2027 EPS estimated at ($0.27), close to the broader consensus of ($0.26). MarketBeat ANGO
• Negative Sentiment: A Seeking Alpha piece titled “AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)” suggests some analysts see limited upside after the recent run, which could temper enthusiasm. Seeking Alpha article

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.